Bleumink G S, van der Molen-Eijgenraam M, Strijbos J H, Sanwikarja S, van Puijenbroek E P, Stricker B H Ch
Drug Safety Unit, Inspectorate for Healthcare, The Hague, The Netherlands.
Clin Neuropharmacol. 2002 Sep-Oct;25(5):290-3. doi: 10.1097/00002826-200209000-00013.
Pleuropulmonary fibrosis is a rare, but well-recognized adverse effect of ergot alkaloids. We report on four patients who developed pleural and/or pulmonary fibrosis during treatment with pergolide and give characteristics of 87 cases with one or more symptoms of serosal fibrosis. Retroperitoneal and pleuropulmonary fibrosis are serious conditions, which are often irreversible after drug withdrawal. Increased awareness may help to diagnose these complications at an earlier stage and to minimize any permanent damage to the patient.
胸膜肺纤维化是一种罕见但已得到充分认识的麦角生物碱不良反应。我们报告了4例在使用培高利特治疗期间发生胸膜和/或肺纤维化的患者，并给出了87例有一项或多项浆膜纤维化症状患者的特征。腹膜后和胸膜肺纤维化是严重疾病，停药后往往不可逆转。提高认识可能有助于在早期诊断这些并发症，并尽量减少对患者的任何永久性损害。
